John W. Higuchi, Director at Lipocine Inc. (LPCN), bought 123,000 shares at $2.05 ($252K) on 2026-04-06, disclosed to the SEC on 2026-04-06.
Director John W. Higuchi executed the largest insider purchase in Lipocine's history by buying 123,000 shares at $2.05 on April 6, 2026. This significant accumulation comes as the stock has crashed nearly 76% over the past 30 days, potentially signaling conviction in a bottoming process.
The stock is trading at $1.94, a 76.14% decline over the last 30 days and a 35.55% drop over the past year, putting it just 7.18% above its 52-week low of $1.81.
Catalysts include the expected submission of a New Drug Application for LPCN 1154 in mid-2026 following Phase III dosing data, and H.C. Wainwright maintaining a Buy rating with a price target of $15. Additionally, the largest insider purchase in the company's history by Director John W. Higuchi may signal a bottom in the stock's valuation.
The stock faces risks from a history of missing earnings estimates, such as the -5.88% earnings miss in Q1 2026, and a short interest of 2.21% that could drive volatility if the thesis fails to materialize.
Clearly above the average filing.
| Filing → |
| LPCN | BUY | 2026-04-07 | $81K | — | Filing → |
| LPCN | SELL | 2021-01-04 | $9K | — | Filing → |
| LPCN | BUY | 2020-03-18 | $70K | — | Filing → |